| Followers | 250 |
| Posts | 14020 |
| Boards Moderated | 3 |
| Alias Born | 07/07/2006 |
Tuesday, February 22, 2011 10:10:15 AM
OXGN Chart .15 two to three potential phase III cancer trials, market cap 20mln
SNSS market cap 100mln+ ?
Buy here and keep 6-12 months.
Recent news:
OXiGENE will provide ZYBRESTAT to National Cancer Institute (NCI) for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone.OXiGENE anticipates that investigators will initiate enrollment in this Phase II study in the first quarter of 2011. The primary endpoint of the study will be progression-free survival, with results expected to become available in early 2013.
Thanks chris.
short interest
01/31/2011 1,770,018 (34.50) 2,468,672 1.00
01/14/2011 2,702,122 0.98 1,215,805 2.22
12/31/2010 2,675,999 1.96 3,319,285 1.00
12/15/2010 2,624,535 34.07 1,151,030 2.28
11/30/2010 1,957,610 (20.63) 2,083,833 1.00
11/15/2010 2,466,563 (11.96) 2,298,385 1.07
SNSS market cap 100mln+ ?
Buy here and keep 6-12 months.
Recent news:
OXiGENE will provide ZYBRESTAT to National Cancer Institute (NCI) for an NCI-sponsored study conducted by the Gynecologic Oncology Group (GOG), an organization dedicated to clinical research in the field of gynecologic cancer. The aim of the trial will be to determine if the combination of ZYBRESTAT and bevacizumab will enhance anti-tumor effects and further delay tumor progression when compared to bevacizumab alone.OXiGENE anticipates that investigators will initiate enrollment in this Phase II study in the first quarter of 2011. The primary endpoint of the study will be progression-free survival, with results expected to become available in early 2013.
Thanks chris.
short interest
01/31/2011 1,770,018 (34.50) 2,468,672 1.00
01/14/2011 2,702,122 0.98 1,215,805 2.22
12/31/2010 2,675,999 1.96 3,319,285 1.00
12/15/2010 2,624,535 34.07 1,151,030 2.28
11/30/2010 1,957,610 (20.63) 2,083,833 1.00
11/15/2010 2,466,563 (11.96) 2,298,385 1.07
To follow my postings on ihub use this link : Ihub person mark
Feedback is allways appreciated, as are other (annotated) picks
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
